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Evidence of meaningful levels of Trypanosoma cruzi in platelet
concentrates from seropositive blood donors
Beatriz Cancino-Faure,1 Roser Fisa,1 Cristina Riera,1 Ibeth Bula,1 Enrique Girona-Llobera,2,3
and Teresa Jimenez-Marco2,3
BACKGROUND: According to the reported cases of
transfusion-acquired Trypanosoma cruzi infection, the
risk of T. cruzi transfusion transmission appears to be
higher with platelet (PLT) products than with other blood
components. The aim of this study was to investigate by
quantitative real-time polymerase chain reaction (qPCR)
the parasitic load detected in leukoreduced plasma and
PLT concentrates collected by apheresis from
seropositive T. cruzi blood donors and compare them
with peripheral whole blood (WB).
STUDY DESIGN AND METHODS: During 2011 to
2013, a prospective study was carried out in a group of
blood donors originating from Chagas-endemic areas but
who are now living on the island of Majorca, Spain.
Leukoreduced plasma and PLT concentrates were
collected by apheresis from seropositive blood donors
with detectable parasitemias in peripheral WB.
RESULTS: Seropositivity was found in 23 of 1201
donors studied (1.9%), and T. cruzi DNA with less than 1
parasite equivalent/mL was detected in peripheral WB in
60.86% (14 of 23) of these. The study in blood
components obtained by apheresis from these donors
showed that T. cruzi DNA with a mean6SD parasitic
load of 5.336 6.12 parasite equivalents/mL was detected
in 100% of the PLT concentrate samples. Parasite DNA
was undetectable in the extract taken from plasma
collected from donors with a positive qPCR in peripheral
WB.
CONCLUSION: The higher parasitic load found in PLT
concentrates compared to plasma and peripheral WB
would explain the higher transfusion transmission risk of
Chagas disease associated with PLT transfusions
described in the reported cases of transfusion-acquired
T. cruzi infection.
A
s a result of globalization and immigration,
emerging blood-borne pathogens such as Tryp-
anosoma cruzi, the causal agent of Chagas dis-
ease, are gaining importance in nonendemic
countries.1-3 The 20 cases associated with transfusion
transmission of T. cruzi reported in North America and
Spain between 1987 and 2011 were all related to platelet
(PLT) concentrates or whole blood (WB), some of which
had even been leukoreduced and irradiated.4 In these
cases, transfusion transmission was confirmed using
hemoculture, polymerase chain reaction (PCR), or serol-
ogy to study the presence of parasites in blood from trans-
fused patients. The retrospective study of the blood
component or WB donors involved in these donations
was in all cases carried out by serology and, additionally
in some cases, using PCR to search for parasite DNA. No
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parasite cultures or PCR DNA amplifications were per-
formed in the units that had already been transfused.5-8
As T. cruzi is present in the human bloodstream as a
trypomastigote, the extracellular form of T. cruzi, experi-
mental assays have suggested that as T. cruzi adheres to
leukoreduction filter fibers, such filters could be used as a
means of reducing this organism in infected blood.9,10
However, the efficacy of leukoreduction to remove para-
sites from red blood cell (RBC) units has not been studied
and it is not known whether this method completely elim-
inates the risk of transfusion transmission.
Even though all blood components are potentially
infectious, there is no empiric evidence in the literature
that RBCs or plasma units are implicated in the transfu-
sion transmission of T. cruzi. Most of the reported cases
have been associated with PLT transfusion.5-8,11
Over the past few decades, innovative devices, new
technologies, and new techniques have been developed in
an attempt to decrease the risk of pathogen transfusion
transmission, as well as to reduce adverse reactions to
transfusion, without altering the quality of blood compo-
nents. One of these techniques is the leukoreduction of
blood products using centrifugation, elutriation, or filtra-
tion, based on size, density, or stickiness of the white
blood cells (WBCs). The generally accepted clinical bene-
fits include prevention of febrile reactions, alloimmuniza-
tion to HLAs, and transmission of infectious agents, as
well as pathogens associated with WBCs, such as cyto-
megalovirus or Epstein-Bar virus.12
During 2011 through 2013, a prospective study was car-
ried out in blood donors who, although living on the Island
of Majorca, originated from Chagas-endemic areas. T. cruzi
serologic screening was performed to identify positive
donors and determine the seropositivity in our geographical
area and to enable their inclusion in a qualitative and quan-
titative parasite study. The parasitic load in PLTs and plasma
concentrated obtained by apheresis was studied by quanti-
tative real-time PCR (qPCR) and compared with the parasit-
emia in peripheral WB.
The aim of this study was to investigate the parasite
loads present in WB and other blood components, such as
plasma and PLTs, from seropositive T. cruzi blood donors
and determine whether or not there are any differences in
parasitemia levels that could explain which component
presents the greatest risk of transmitting pathogens
through transfusion.
MATERIALS AND METHODS
Blood donors
During 2011 through 2013, a total of 1201 blood donors
who originated from Chagas-endemic areas, but are now
living in the Balearic Islands, were tested for T. cruzi–spe-
cific antibodies in the Balearic Islands Blood Bank (BIBB).
All donors with positive serology who had not been previ-
ously treated for the parasite, and consented to be
included in the study, were analyzed for parasite load in
peripheral WB and blood components, plasma, and PLTs
obtained by apheresis. All of them were permanently
rejected as donors for patient transfusions.
Ethics statement
This study was approved by the ethical committees of the
participating institutions, the Balearic Island Ethic Com-
mittee and the Research Ethics Committee of the Univer-
sity of Barcelona. Written informed consent was obtained
from all donors for the screening and apheresis study.
In accordance with the Spanish and European regula-
tions, our standard operating procedure for donors who
were seropositive for T. cruzi by the screening test at the
blood bank involved permanent deferral for these individ-
uals. Additionally, donors were immediately referred to
the Infectious Disease Unit at the University Hospital in
Majorca for follow-up and treatment. Treatment was
never delayed by participation in this study.
Screening study
Five milliliters of serum was obtained for serologic study
and 10 mL of peripheral WB was collected and immedi-
ately mixed with an equal volume of 6 mol/L guanidine
hydrochloride-0.2 mol/L EDTA buffer (Sigma, St Louis
MO) for molecular study. The mixture guanidine-EDTA-
WB (GEB) was stored at 4C until the DNA purification.
GEB samples were not boiled.13
Apheresis study
Cell separators and procedures
Fenwal Amicus Version 3.11. Fenwal Amicus (Fresenius
Kabi, Bad Homburg, Germany) is an apheresis device
capable of dual- and single-needle plateletpheresis. The
PLT-rich plasma is separated from the RBCs and WBCs in
a bell-shaped chamber with two compartments. After the
elutriation process, PLT-rich plasma is pumped to the col-
lection chamber as so-called dry PLTs, that is, high-
concentration plasma-reduced PLTs. At the end of the
process, the PLTs are manually resuspended by shaking
and adding PLT-poor plasma and then transferred to the
storage bags with additive solution (AS) at a ratio of
approximately 35% plasma and 65% AS.
Two Amicus devices, Software Version 3.11, set code
REF R4R2337, were used for the study. All procedures used a
WB:ACD ratio of 11:1 (i.e., 1 part ACD per 11 parts WB) and
citrate infusion flow of 1.35 mL/kg/min. The maximum inlet
and return rates were 110 and 120 mL/min, respectively.
Trima Accel Version 5.22. Trima Accel (Terumo BCT,
Lakewood, CO) is a single-needle, continuous-separation
apheresis device. Trima Accel Version 5 has a single-stage
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separation channel with all of the blood components
flowing in one direction. The blood components separate
into layers over the entire circumference according to spe-
cific gravity. PLTs are harvested from the component layer
between RBCs and plasma, leukoreduced with the
process-controlled leukoreduction system, and collected
in the final storage container.
Three Trima Accel machines, Version 5.22, Set Code
REF 80420, were used for the study. All procedures used a
WB:ACD ratio of 11:1 (i.e., 1 part ACD per 10 parts WB)
and maximum citrate infusion flow of 1.1 mL/min/L total
blood volume. The maximum inlet and return rates were
100 and 140 mL/min, respectively. The PLT concentrates
were collected in small amounts of plasma and diluted in
AS at the end of the procedure to maintain a ratio of
approximately 35% plasma and 65% AS.
Haemonetics MCS1. The Haemonetics MCS1 system
(Haemonetics Corp., Braintree, MA) uses intermittent-
flow centrifugation to collect plasma, PLTs, WBCs, or
RBCs. The grenade-shaped plasmapheresis rotation bowl
is used for plasma collection. WB enters the bowl through
the stationary tube and forms vertical layers of plasma
and RBCs. As the bowl fills, packed cells accumulating on
the outer wall displace the plasma inward, pushing it out
through the effluent tube. When the bowl is full of RBCs,
it must be stopped and emptied before the process can be
repeated.
Two Haemonetics MCS1 apheresis machines, Set
Code REF 792 P, PLT-poor plasma, were used for the study.
All procedures used a WB:ACD ratio of 12:1 (i.e., 1 part
ACD per 11 parts WB). The maximum inlet and return
rates were 100 and 150 mL/min, respectively.
Preparations of blood components
Plateletpheresis and PLT-plasmapheresis donations were
performed on selected donors using Trima and Amicus
automatic cell separators. The mean PLT unit volume col-
lected in the plateletpheresis procedures was 300 mL. PLT
components containing 3.5 3 1011 were suspended in
approximately 35% plasma and 65% PLT AS (PAS IIIM;
Terumo BCT). The mean volume of plasma unit collected
in the PLT-plasmapheresis procedures was 300 mL. All
PLT and plasma components collected were leukoreduced
by in-process leukoreduction (leukoreduction system
chamber for Trima and elutriation for Amicus).
Plasmapheresis donations were carried out using the
Haemonetics MCS1. The mean plasma volume collected
was 600 mL, and leukoreduction was performed using a
leukoreduction plasma filter (Plasmaflex Plas 4, Maco-
Pharma, Mouvaux, France) at the end of the collection
procedure.
A total of eight apheresis procedures were performed
from which six plasma and six leukoreduced PLT concen-
trates were obtained. Three blood donors with detectable
parasitemia in peripheral WB consented to donate blood
components by apheresis to study the parasite load. Each
blood donor included in the study gave blood compo-
nents in different donations. The first underwent one pla-
teletpheresis procedure; the second one plasmapheresis
and two PLT-plasmapheresis procedures; and the third
one plasmapheresis, one plateletpheresis, and two PLT-
plasmapheresis procedures. Within the apheresis samples,
ten milliliters of GEB was obtained to determine the basal
parasitic load (Table 2).
Samples were collected in the BIBB and sent, no
more than 2 days after the donation, to the Parasitology
Laboratory of the Universitat de Barcelona for molecular
analysis. The samples of plasma, PLTs, and GEB were sent
at 220C, at room temperature and 4C, respectively, and
once received were immediately processed for DNA
extraction.
Serologic study
The serologic study for detection of specific T. cruzi anti-
bodies was performed by an enzyme-linked immunosor-
bent assay (ELISA) test for qualitative detection of total
antibodies to T. cruzi in human serum or plasma (Bio-
ELISA Chagas, Biokit, Werfen Group, Barcelona, Spain)
with recombinant antigen of T. cruzi and another com-
mercially available ELISA test system (Ortho Clinical Diag-
nostics, Raritan, NJ) with antigen of a total extract of
epimastigotes from T. cruzi in BIBB. Confirmation was
performed in the Parasitology Laboratory of the Universi-
tat de Barcelona by a third diagnostic method using West-
ern blot with antigen of a total extract of epimastigotes
from the T. cruzi Maracay strain.14
Molecular study
DNA extraction
For each sample, DNA was extracted in triplicate (Table 2)
from different samples: 200 mL of GEB from all seroposi-
tive donors (screening sample), 200 mL of GEB at the
moment of apheresis (basal sample), 200 mL of PLT con-
centrate, and 200 mL of plasma concentrate (the last two
obtained by apheresis). The extraction was performed
with a PCR template preparation kit (High Pure, Roche,
Mannheim, Germany) and eluted in 200 mL of elution
buffer according to the manufacturer’s instructions. The
eluate was stored at220C for qPCR analysis. To build the
standard curve for quantification of parasitic loads, DNA
from a culture of epimastigotes of T. cruzi (Maracay strain,
1 3 105 parasite/mL) was extracted in the same way as
previously reported.
qPCR assay
Five microliters of extracted DNA was amplified in tripli-
cate by qPCR (Table 2) in a qPCR instrument (LightCycler
480, Roche) device. The primers, probes, and conditions of
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the technique were as described by Piron and coworkers15
with some modifications. Briefly, the following were used,
primers Cruzi 1 and Cruzi 2 and probe Cruzi 3, which was
labeled with 6-carboxyfluorescein and minor groove
binder. The final concentrations in the PCR mixture were
as follows: 13 LightCycler 480 Probes Master (Roche), 750
nmol/L each T. cruzi primer, and 250 nmol/L for the
T. cruzi probe in a 20-mL reaction volume. Detection of the
RNase P human gene (0.33 RNase P detection reagents,
Life Technologies, Austin, TX) was included as an internal
control of amplification in multiplex qPCR, and a non-
template sample and DNA from seronegative human
blood were included in each run as a negative control.
A sample was considered valid when the internal con-
trol was efficiently amplified and was considered positive
when the quantification cycle (Cq) was less than or equal
to 40 and if at least three of the nine replicates studied for
each sample were amplified.16 A standard curve was con-
structed with 1-in-10 serial dilutions of total DNA
extracted from Maracay strain (1 3 105- 0.1 parasite
equivalents/mL). The parasitic load of every sample was
calculated using the LightCycler 480 software through the
second derivative maximum method.
RESULTS
Screening study
From a total of 1201 blood donors coming from Latin Amer-
ica, 23 were T. cruzi seropositive by the three serologic tests
,which corresponded to 1.91% of prevalence with respect to
the total donor population. The Bolivian population with
16.03% (17 of 106; 95% confidence interval [CI], 10.1-24.2)
seropositivity had the highest prevalence (Table 1).
Parasite DNA was detected in peripheral WB by qPCR
in 14 of the 23 seropositive donors, which corresponds to
60.86% (95% CI, 40.7-77.9) positivity in chronic patients
(Table 1). The mean6 SD Cq in these screening samples
(GEB) was 34.356 2.87, which implies a parasitic load of
0.396 0.2 parasite equivalents/mL.
Apheresis blood components study
The qPCR study of the PLTs indicated that all samples
amplified with 100% positivity in all the extractions (18 of
18) and 100% positivity in all replicates performed (54 of
54), with a significant mean6SD parasitemia of
5.336 6.12 parasite equivalents/mL. In contrast, parasite-
mia was undetectable in all extract from plasma samples
with 0% positivity in all the extractions (0 of 18) for para-
site DNA, with 0% of amplification in all replicates (0 of
54). The peripheral WB (basal sample) obtained on the
day of plasma and PLT donation by apheresis showed that
all samples were positive with a mean6 SD parasitemia of
0.426 0.32 parasite equivalents/mL (Table 2), although
not all the replicates amplified in five extractions (59 of 72
replicates amplified by qPCR, 81.9%; 95% CI, 71.3-89.2).
DISCUSSION
Blood transfusion is the second most common mecha-
nism for the transmission of T. cruzi in endemic areas and
the first in nonendemic areas. The transfusion transmis-
sion risk of Chagas disease is thought to depend on multi-
ple factors, including the level of parasitemia in the donor,
the type of component transfused, and perhaps the strain
of the parasite.17,18 In Spain, of the reported cases of T.
cruzi transfusion transmission, all the patients were trans-
fused with PLT concentrates and all the donors implicated
in the donation originated from Chagas-endemic areas,4
three of the four donors from Bolivia and one from Brazil.
The serologic screening performed in our study in the
Balearic Islands showed that 1.91% of the blood donors
coming from Chagas-endemic areas were seropositive.
The largest Latin American population living in the Bale-
aric Islands originates from Argentina and is the Latin
American group that donates blood most often; however,
Bolivian donors have the highest positive detection rate
for T. cruzi at 16.03%. These results are consistent with the
2007 study performed in Catalonia, Spain, by Piron and
colleagues,19 in which the seroprevalence of donors stud-
ied was 0.62%, and the highest positive detection rate for
T. cruzi (10.2%) was in Bolivian blood donors.
The detection of T. cruzi by molecular methods, such
as by PCR in blood samples, has high specificity and sen-
sitivity. This technique has been successfully used in the
diagnosis of acute chagasic disease for more than 15
years;20 however, due to low parasitemia, the sensitivity
and reproducibility of the technique decreases in chronic
patients. The sensitivities reported in this group of
TABLE 1. Results of T. cruzi serologic screening of blood donors from Chagas-endemic areas living on the Island of
Majorca and presence of T. cruzi DNA in peripheral WB by qPCR in seropositive blood donors studied
Argentina Ecuador Bolivia Venezuela Total
Donors 649 362 106 84 1201
Percentage of donors* 1.42 0.78 0.24 0.19 0.66
Seropositive donors† 4 (0.61) 1 (0.27) 17 (16.03) 1 (1.19) 23 (1.91)
Presence of T. cruzi DNA† 3 (75) 0 (0) 10 (58.8) 1 (100) 14 (60.86)
* Percentage of Latin American donors with respect to the total donor population.
† Data are reported as number (%).
CANCINO-FAURE ET AL.
4 TRANSFUSION Volume 00, Month 2015
patients are between 20 and 60% and depend on the con-
ditions under which the technique is performed.15,21 In
our study using a quantitative, validated, highly sensitive
real-time PCR we found 60.86% (95% CI, 40.7-77.9) posi-
tivity in 23 seropositive blood donors living in the Balearic
Islands. This percentage is slightly higher than the 41%
found in 2007 by Piron and coworkers15 in seropositive
blood donors in Catalonia and similar to the 56.5% found
in 2011 by Schijman and colleagues,21 using qPCR in
chronic patients from endemic areas.
Low and oscillating parasitemias are described in
chronic chagasic patients15,21 and are consistent with the
results found in peripheral WB in our pool of seropositive
donors, a group in which parasitemias were lower than 1
parasite equivalent/mL. In these samples it was observed
that not all replicates amplified according to the low or
nonexistence of parasites. Consequently, it is strongly rec-
ommended that replicates of DNA extractions and qPCR
of WB are performed when a diagnosis is made to increase
the possibility of finding positives results, especially when
working with small volumes of samples.
Our extract from plasma results did not show any
positive amplifications of the parasite DNA in any of the
donor samples (0/6). By contrast, in the leukoreduced PLT
concentrates, we found parasitic load values of 5.336 6.12
parasite equivalents/mL, with a parasitic load range of
0.72 to 16.73 parasite equivalents/mL, more than five
times greater than the parasitic load of the peripheral WB.
The qPCR results were positive in all samples (6/6) and,
interestingly, 100% of qPCR replicates of all samples stud-
ied (54/54) were positives. It is possible that this percent-
age would decrease if no previous screening for the
presence of parasite in peripheral WB was performed to
select the studied individuals, as in the 2009 study carried
out by Dzib and colleagues, 22 using a conventional PCR
of minicircle kDNA in blood components leukoreduced
by centrifugation from 21 units of seropositive donors,
which found 50% positivity in PLT concentrates. Results
published in 2005 by Coronado and coworkers23 indicate
that the circulating DNA belongs to living parasites and
not to circulating DNA from the remains of dead parasites,
because this is rapidly degraded. It would be interesting to
study parasite viability to discriminate between viable and
nonviable parasites.
Leukoreduction is considered by some authors to be a
good method for reducing the T. cruzi transfusion transmis-
sion risk, but more detailed studies will be needed to con-
firm this theory. A report published by Hernandez-Becerril
and colleagues,24 in 2005, studied 70 PLT and RBC compo-
nents leukoreduced from seropositive blood donors by con-
ventional PCR and hemoculture. However, no parasitemia
was detected by either of the methods; this factor could be
attributed to the leukoreduction. Similarly, in 2006 Cardo
and Asher9 reported a filtration assay study in which T. cruzi
trypomastigotes spiked in plasma remained in the leukore-
duction filters as a result of adherence. In 1995, Moraes-
Souza and coworkers,10 using leukoreduction filters in
spiked human blood, showed that this process reduced the
number of T. cruzi. By contrast, in our study, leukoreduction
was not entirely effective at eliminating the parasitic load; in
fact, the parasite loads detected in PLTs obtained by aphere-
sis were higher than the parasite load in peripheral WB. A
study performed by Dzib and coworkers22 in 2009 reported
that leukoreduction by centrifugation did not eliminate
T. cruzi from infected blood units. In fact, they found para-
site DNA in RBCs, buffy coat, and PLT concentrates.
Certainly, the risk of T. cruzi transmission per infected
blood product transfused is estimated to be from 10% to
25%, with PLT products having a much higher risk than
RBCs, frozen plasma, or cryoprecipitated products.4,9,25 In
fact, there have been no reported cases of transfusion
transmission through blood components that were frozen
and stored at 220C or RBCs, even though a report pub-
lished by Martin and coworkers26 in 2014 observed that
T. cruzi in spiked human blood and in infected culture cells
was able to survive long periods of storage at 14C and
280C, suggesting that T. cruzi–infected blood or tissues
stored under these conditions are potentially infectious.
The reason why we detected parasite DNA in PLTs,
and not in plasma concentrates obtaining by apheresis
from the same donor who was PCR positive in peripheral
blood, could be related to the method that apheresis
machines use to process WB. Basically, apheresis machines
use centrifugation and filtration, the first as a method of
TABLE 2. Peripheral WB and apheresis blood components from T. cruzi–seropositive blood donors and
quantification results of parasitic load obtained by qPCR
Sample
Total of DNA
extractions by
sample*
Total of
qPCR
replicates†
Positives
replicates
amplified
Positives
samples Mean Cq‡
Quantification of parasitic load
Mean§ Range§
GEB (n5 8) 24 72 59/72 8/8 (100%) 35.062.93 0.4260.32 0.04-0.93
Plasma (n5 6) 18 54 0/54 0/6 (0%) >40 Nondetectable Nondetectable
PLTs (n56) 18 54 54/54 6/6 (100%) 30.762.42 5.3366.12 0.73-16.73
* Three extractions of DNA of each sample were performed.
† Three replicates of each DNA extracted were amplified by qPCR.
‡ Mean6SD of all replicates. Value of qPCR expressed in Cq.
§ Expressed in parasites equivalent/mL.
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separating and concentrating the selected blood compo-
nent, through centrifugation that uses differences in spe-
cific gravity or density to separate and isolate blood
components, and the second, filtration as a method for
reducing the WBC count in PLT concentrates (some
machines also use elutriation as an alternative to filtra-
tion). Filtration takes advantage of differences in particle
size to separate and, as has already been stated, centrifuga-
tion is based on the specific gravity of blood cells. The try-
pomastigote form of T. cruzi has a size of 16 to 20 mm18
and a specific gravity between PLTs and WBCs.27,28 Accord-
ing to these data, it is reasonable to think that, since PLTs
are concentrated along with WBCs throughout the aphere-
sis procedure, trypomastigotes are concentrated along
with WBCs in the PLT fraction rather than in the plasma or
RBC fraction. Therefore, the PLT fraction initially collected
by apheresis contains WBCs, although it is leukoreduced
during the procedure by elutriation or after the procedure
by filtration. However, it is important to note that, despite
leukoreduction (i.e., 13 106/L WBCs) the level of residual
WBCs in leukoreduced PLT concentrates could be up to 1
3 106 per unit according to our national standards.
Accordingly, if a considerable number of WBCs are still
present in leukoreduced PLT products, it is logical to think
that parasites can also remain.
Using laboratory techniques, in seropositive T. cruzi
blood donors we have seen that PLTs are the component
with the main parasitic load; therefore, it could explain
what is observed in clinical cases of transfusion transmis-
sion of Chagas disease reported in the literature, in which
PLT concentrates are the major component implicated in
transmission.4-9,29 It would be challenging to investigate
the role of new pathogen inactivation technologies, in
reducing the parasite load in blood components, for exam-
ple, PLT concentrates, obtained from seropositive T. cruzi
donors, and to study whether they are effective in these
samples, because so far they have only been studied exper-
imentally in blood components spiked with T. cruzi. 30,31
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